VINCRISTINE SULFATE - Generic Drug Details

What are the generic drug sources for vincristine sulfate and what is the scope of patent protection?

Vincristine sulfate is the generic ingredient in six branded drugs marketed by Acrotech, Lilly, Teva Parenteral, Bristol Myers Squibb, Abic, Abraxis Pharm, Fresenius Kabi Usa, Hospira, and Teva Pharms Usa, and is included in thirteen NDAs. Additional information is available in the individual branded drug profile pages.

There are eight drug master file entries for vincristine sulfate. One supplier is listed for this compound.

Summary for VINCRISTINE SULFATE

US Patents:	0
Tradenames:	6
Applicants:	9
NDAs:	13
Drug Master File Entries:	8
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	482
Patent Applications:	4,563
What excipients (inactive ingredients) are in VINCRISTINE SULFATE?	VINCRISTINE SULFATE excipients list
DailyMed Link:	VINCRISTINE SULFATE at DailyMed

Recent Clinical Trials for VINCRISTINE SULFATE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Children's Oncology Group	PHASE2
City of Hope Medical Center	PHASE2
National Cancer Institute (NCI)	PHASE2

See all VINCRISTINE SULFATE clinical trials

Pharmacology for VINCRISTINE SULFATE

Drug Class

Vinca Alkaloid

Medical Subject Heading (MeSH) Categories for VINCRISTINE SULFATE

Antineoplastic Agents, Phytogenic

Tubulin Modulators

Anatomical Therapeutic Chemical (ATC) Classes for VINCRISTINE SULFATE

L01CA	Vinca alkaloids and analogues
L01C	PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS
L01	ANTINEOPLASTIC AGENTS
L	Antineoplastic and immunomodulating agents

US Patents and Regulatory Information for VINCRISTINE SULFATE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Abraxis Pharm	VINCRISTINE SULFATE	vincristine sulfate	INJECTABLE;INJECTION	070411-001	Sep 10, 1986		DISCN	No	No
Acrotech	MARQIBO KIT	vincristine sulfate	INJECTABLE, LIPOSOMAL;INTRAVENOUS	202497-001	Aug 9, 2012		DISCN	Yes	No
Hospira	VINCRISTINE SULFATE	vincristine sulfate	INJECTABLE;INJECTION	071561-001	Apr 11, 1988		DISCN	No	No
Fresenius Kabi Usa	VINCRISTINE SULFATE	vincristine sulfate	INJECTABLE;INJECTION	076296-001	Dec 20, 2002		DISCN	No	No
Fresenius Kabi Usa	VINCRISTINE SULFATE	vincristine sulfate	INJECTABLE;INJECTION	076401-001	Oct 28, 2003		DISCN	No	No
Lilly	ONCOVIN	vincristine sulfate	INJECTABLE;INJECTION	014103-002	Approved Prior to Jan 1, 1982		DISCN	Yes	No

Expired US Patents for VINCRISTINE SULFATE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Acrotech	MARQIBO KIT	vincristine sulfate	INJECTABLE, LIPOSOMAL;INTRAVENOUS	202497-001	Aug 9, 2012	5,543,152
Acrotech	MARQIBO KIT	vincristine sulfate	INJECTABLE, LIPOSOMAL;INTRAVENOUS	202497-001	Aug 9, 2012	7,887,836
Acrotech	MARQIBO KIT	vincristine sulfate	INJECTABLE, LIPOSOMAL;INTRAVENOUS	202497-001	Aug 9, 2012	5,741,516
Acrotech	MARQIBO KIT	vincristine sulfate	INJECTABLE, LIPOSOMAL;INTRAVENOUS	202497-001	Aug 9, 2012	7,247,316
Acrotech	MARQIBO KIT	vincristine sulfate	INJECTABLE, LIPOSOMAL;INTRAVENOUS	202497-001	Aug 9, 2012	6,723,338
Acrotech	MARQIBO KIT	vincristine sulfate	INJECTABLE, LIPOSOMAL;INTRAVENOUS	202497-001	Aug 9, 2012	5,814,335

Market Dynamics and Financial Trajectory for Vincristine Sulfate

Last updated: February 19, 2026

Vincristine sulfate is a chemotherapy drug used primarily to treat leukemia, lymphomas, and other cancers. Its production, patents, and market presence are influenced by multiple factors including patent expirations, competition, and regulatory landscapes.

Patent Status and Market Exclusivity

Vincristine sulfate is a cytotoxic agent derived from the periwinkle plant. Initially, it was patented in the mid-20th century; however, patents have expired or are nearing expiration in most jurisdictions. This has opened the market to biosimilars and generic manufacturers, increasing competitive pressure.

• Patent expiration: Mainly expired by 2010 in the U.S. and EU.
• Generics and biosimilars: Numerous companies now produce generic vincristine sulfate, reducing prices and margins.

Supply Chain and Manufacturing Trends

Most production occurs through synthetic and semi-synthetic processes. The manufacturing complexity is moderate due to the plant-derived nature and the need for strict quality controls.

• Key producers: Multiple generic firms, with no dominant patent holder post-expiry.
• Supply risks: Limited, but quality standards impact market entry for new manufacturers.

Regulatory Environment

Regulators such as the FDA (U.S.) and EMA (EU) require rigorous testing and manufacturing standards for approval of generic versions.

• Approval rates: High for generics post-patent expiry.
• Pricing regulation: Price ceilings and reimbursement policies influence revenue.

Market Size and Revenue Trajectory

Global demand for vincristine sulfate has been stable, driven by ongoing need in chemotherapy protocols.

Year	Estimated Global Market Size (USD million)	CAGR
2020	120	—
2025 (projected)	160	8.0%

• 2020 market size estimated at USD 120 million.
• Projected CAGR (2021-2025): 8.0%, driven by increasing cancer treatment rates and integration into combination chemotherapies.

Pricing and Revenue Impact

Generic competition has driven prices downward, impacting revenue for brand-name producers.

• Average price per vial (2010): USD 250.
• Average price per vial (2022): USD 80.
• Revenue trends: Decline observed in markets dominated by generics.

R&D and Innovation Outlook

Limited innovation has occurred, with focus mostly on combination therapies. Advances in targeted therapy compounds may reduce reliance on vincristine sulfate over time.

• New formulations: Trial phases for less toxic derivatives.
• Clinical pipeline: Few novel formulations, indicating limited R&D investment.

Competitive Landscape

The market comprises multiple generic manufacturers with similar cost structures.

• Top players: Teva, Sandoz (Novartis), Hospira (Pfizer).
• Market share: No single company exceeds 20% post-generic entry.

Future Market Drivers and Risks

Drivers:

• Continued use in established chemotherapy protocols.
• Increasing global cancer incidence in low- and middle-income countries.

Risks:

• Competition from novel targeted therapies reducing reliance.
• Regulatory challenges in emerging markets.
• Price pressures from increasing biosimilar entries.

Key Financial Implications

• Revenue growth prospects are constrained by price erosion.
• Margins decline due to commoditization.
• Investment in niche indications or combination therapies may sustain profitability.

Summary

Vincristine sulfate's market is mature with declining revenues driven by generic competition and pricing pressures. Demand remains steady owing to its established role in cancer therapy. Future growth hinges on regulatory developments, innovation in formulations, and changes in treatment protocols.

---

Key Takeaways

• Patent expirations have led to increased generic competition and price reductions.
• The global market size is projected to grow at 8% CAGR, driven by cancer treatment demand.
• Revenue margins are declining due to commoditization and price competition.
• Limited innovation suggests the market will remain stable but competitive.
• Future growth depends on treatment protocol shifts and potential new formulations.

---

FAQs

1. What factors have most impacted vincristine sulfate's market share?
Patent expirations, generic entry, and price competition.

2. How do regulatory standards influence global supply?
Strict approval processes in major markets slow new entrants but ensure quality, maintaining supply stability.

3. Are biosimilars a significant threat?
Yes, biosimilars increase competition and exert downward pressure on prices.

4. What are the primary drivers of demand in the coming years?
Rising cancer incidence globally and continued use in chemotherapy protocols.

5. What potential innovations could alter the market trajectory?
Development of less toxic formulations and novel combination therapy regimens.

---

References

[1] MarketResearch.com. (2022). Global Vincristine Sulfate Market report.
[2] FDA. (2022). Pharmaceutical regulations and approval process.
[3] WHO. (2021). Global cancer statistics.
[4] Sandoz. (2021). Biosimilar drug pipeline.
[5] IMS Health. (2022). Pharmaceutical market data.